Investor Briefing · Series II · Confidential

Europe's first
longevity infrastructure
platform.

We are not raising capital. We are choosing partners.

A category that does not yet exist — real estate, longevity and artificial intelligence, built into one compounding platform. We are admitting a small circle of partners to build it from the ground up.

Apply to be considered → Read the thesis →
The Ground
Real Estate
Longevity-grade residences across a seven-country footprint — four sequenced flagships (Spain, Switzerland, Portugal, Saudi Arabia), beginning with Spain.
The Purpose
Longevity
Longer, better lives — the one demand curve that only steepens.
The Multiplier · AI
A.I.
Proprietary AI that learns each guest and turns data into recurring returns.
The Convergence · One compounding engine

Three forces.
One flywheel.

Held separately, each is a good business. Held together, they feed one another — and turn a portfolio of buildings into a system that learns, retains, and compounds.

The building creates the guests. The guests generate longitudinal health data. The data trains an intelligence no competitor can assemble after the fact. And that intelligence brings each guest back — turning a one-time stay into a lifelong relationship, and real estate yield into recurring, defensible income. This is not technology bolted onto property. It is a single living system, designed around one purpose: longer, better lives, owned as infrastructure.
The Longevity Engine
01Real Estate
02Guests
03Data
04Intelligence
05Returns
i
The real estate creates the guests
Longevity-grade residences and clinics — appraised, financeable assets — rolling out across a seven-country footprint — four sequenced flagships — beginning in Spain. They are also the acquisition channel for a discerning clientele.
Asset
ii
The guests create the data
Every stay produces longitudinal biomarker data. Aggregated across sites, it becomes one of Europe's most valuable clinical datasets — at zero additional capex.
Data
iii
The data trains the intelligence
A personalised model learns each guest's biology — and learns the business: pricing, demand, and the precise moment a return visit matters most.
Model
iv
The intelligence compounds the return
It brings each guest back two to three times a year, makes income forecastable enough to re-rate the cost of capital, and creates a dataset that can be monetised on its own.
→ Annuity
The real estate — four flagships, seven-country footprint
01SpainFlagship · 2029 · under way
02SwitzerlandFlagship · 2031
03PortugalFlagship · 2032
04CroatiaPipeline
05FrancePipeline
06ScandinaviaPipeline
07Saudi ArabiaFlagship · 2033
The shape of the opportunity
You enter through real estate. You compound through intelligence. And the demand underneath it all — the wish to live longer and better — is the one curve that never flattens.
Read the AI strategy →
Longevity · The Treatments

Longevity Medicine
at the frontier of age.

This is what the buildings are built around — a clinical programme that treats ageing as something to measure, slow, and even begin to reverse. Delivered under licensed medical supervision, and tuned to each guest by the platform's own intelligence.

i
Biological age, measured
A full diagnostic baseline — genomic, biomarker and imaging panels — establishing each guest's true biological age and the trajectory ahead.
ii
Regenerative & cellular therapies
Evidence-led regenerative protocols — cellular, peptide and mitochondrial — that aim to restore function rather than merely manage decline.
iii
Metabolic & hormonal optimisation
Precision metabolic, hormonal and nutritional programmes that rebuild the body's baseline, refined visit after visit.
iv
Longevity pharmacology
Access to the emerging frontier — senolytic and longevity-targeted compounds — through clinical and research partnerships, applied responsibly.
v
Intelligence-guided, always
Every protocol is personalised and continuously refined by the platform's model — so care grows more precise with each visit and each data point.
Why it is groundbreaking
No European platform has yet brought diagnostics, regenerative medicine and longevity pharmacology under one roof — and under one intelligence. ETERRA is building the place where the science of a longer life actually lives.

Protocols are delivered by licensed clinicians; availability varies by site, indication and regulation. Nothing here constitutes a medical claim or a promise of outcome.

A Category of One · Why it cannot be copied

This cannot be assembled
after the fact.

Capital can buy buildings. It can license software. It cannot buy years of a person's biology, or the trust that comes with it. That is the advantage — and it deepens every single day.

i
Biological data that cannot transfer
Years of longitudinal biomarker data are not portable. To leave is to lose your entire health history and start from zero. No guest does that — so the relationship, and the asset, only strengthen with time.
ii
Intelligence as the sales force
No other operator has an automated, data-driven channel that brings the right guest back at the right moment. The model does the work that marketing cannot — quietly, and at near-zero marginal cost.
iii
The convergence itself
Real estate developers do not hold clinical data. Health-tech firms do not own the buildings. ETERRA sits at the one intersection — and a latecomer would need a decade of operations to stand where we already stand.
Why this matters to a partner
Most assets are defended by price. This one is defended by time, trust, and biology — the three things capital cannot shortcut.
The Standard · Who we admit

We are auditioning
investors.

A platform like this is built once. The partners we choose will help shape it for a decade. So we choose the way we would choose a co-founder — for conviction, patience, and the wish to build something that outlives the return. The capital matters less than the character behind it.

We are not assembling a cap table of strangers. Series II admits a small, deliberate circle of partners — people who understand that the finest things compound slowly, who value discretion, and who would rather own a defining asset for a decade than trade a good one in a year. If that is you, we would like to know you.
—
You think in decades, not quarters
The flywheel rewards patience. The partners we admit are building wealth that should still mean something to the next generation.
—
You believe in the purpose, not only the upside
Longevity is personal before it is financial. Our partners want to be part of how Europe ages — with grace, science, and dignity.
—
You bring more than money
Networks, judgement, relationships, a steady hand in difficult moments. The best partners make the platform better simply by being on it.
—
You value discretion and trust
This is a small room by design. What is shared inside it stays inside it. Confidentiality is not a clause; it is the culture.
The invitation, plainly
Admission is mutual. You are deciding whether ETERRA is worthy of your capital — and we are deciding whether we will build the next decade together.
The Economics · 2026 – 2030

Enter at real-estate prices.
Own an intelligence platform.

Today's entry price values the bricks. It prices neither the data asset, nor the recurring AI revenue, nor the lower cost of capital that intelligence unlocks. Those layers come with the building.

Valuation componentContribution
Base platform EV — real estate only~€430M
+ AI companion (recurring revenue, 5× ARR)+€60–95M
+ Longevity data asset, capitalised+€40–80M
+ Lower cost of capital, capitalised+€50–80M
Platform EV with intelligence€580–685M
Entry · 2026
€100–120M
Pre-money — AI layers not yet priced in
Target EV · 2030
€580–685M
Base platform plus all three intelligence layers
Implied multiple
4.8–5.7×
Indicative · ~4-year hold · before RAIF carry
Cost to build the AI
~€1.5M
Over 3 years · under 0.5% of platform capex
The quiet asymmetry
You buy the property at property multiples — and the intelligence platform comes with it. The asymmetry is the whole point.
By Invitation · Confidential · Direct

This is an application,
not a transaction.

Tell us who you are and why this resonates. If there is mutual fit, a forty-five-minute conversation follows — by call or in person. Admitted partners are then granted the portal: the full dossier, and the data room behind a mutual NDA. No pitch. Just the beginning of a decision we both make.

Apply to be considered → Ask a question first →
Enquiries
contact@eterra.ch
Admitted partners
Enter the portal →
Office
ETERRA AG · Sumpfstrasse 15 · CH-6312 Steinhausen · Switzerland